Signature Estate & Investment Advisors’s Avid Bioservices, Inc. Common Stock CDMO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-13,001
Closed -$92.8K 539
2024
Q2
$92.8K Buy
13,001
+286
+2% +$2.19K ﹤0.01% 499
2024
Q1
$85.2K Buy
+12,715
New +$87.5K ﹤0.01% 175
2023
Q4
Sell
-12,715
Closed -$120K 195
2023
Q3
$120K Hold
12,715
﹤0.01% 170
2023
Q2
$178K Hold
12,715
0.01% 170
2023
Q1
$239K Sell
12,715
-29
-0.2% -$476 0.01% 164
2022
Q4
$175K Hold
12,744
0.01% 180
2022
Q3
$244K Hold
12,744
0.01% 150
2022
Q2
$194K Hold
12,744
0.01% 166
2022
Q1
$260K Hold
12,744
0.01% 145
2021
Q4
$372K Hold
12,744
0.02% 131
2021
Q3
$275K Buy
12,744
+29
+0.2% +$700 0.01% 143
2021
Q2
$326K Hold
12,715
0.01% 132
2021
Q1
$232K Hold
12,715
0.01% 152
2020
Q4
$147K Hold
12,715
0.01% 155
2020
Q3
$97K Hold
12,715
0.01% 148
2020
Q2
$83K Buy
+12,715
New +$71K 0.01% 137
2014
Q3
Sell
-1,600
Closed -$21K 72
2014
Q2
$21K Buy
+1,600
New +$20.2K 0.01% 60

Other funds holding CDMO

Signature Estate & Investment Advisors's CDMO Position: Q3 2024 in Review

Signature Estate & Investment Advisors sold out of Avid Bioservices, Inc. Common Stock (CDMO) in Q3 2024, closing a stake of 13,001 shares — an estimated $92.8K sold.

Signature Estate & Investment Advisors first reported a position in CDMO in Q2 2014 and held it in 17 quarters. The position peaked at $372K in Q4 2021. 172 funds tracked by Wall St. Rank hold CDMO as of Q3 2024.

  • Signature Estate & Investment Advisors reported no remaining Avid Bioservices, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Signature Estate & Investment Advisors sold 13,001 Avid Bioservices, Inc. Common Stock shares in Q3 2024, an estimated $92.8K.
  • Signature Estate & Investment Advisors first reported a position in Avid Bioservices, Inc. Common Stock in Q2 2014 and held it in 17 quarters.
  • Signature Estate & Investment Advisors's Avid Bioservices, Inc. Common Stock position peaked at $372K in Q4 2021.
  • 172 funds tracked by Wall St. Rank held Avid Bioservices, Inc. Common Stock as of Q3 2024.

Based on Signature Estate & Investment Advisors's 13F filing for Q3 2024, filed 6 Nov 2024.